179 related articles for article (PubMed ID: 35669373)
1. Exploration of the Effect of Icariin on Nude Mice with Lung Cancer Bone Metastasis via the OPG/RANKL/RANK System.
Ruilian Z; Ying G; Hongmei S; Lihua G
Comput Math Methods Med; 2022; 2022():2011625. PubMed ID: 35669373
[TBL] [Abstract][Full Text] [Related]
2. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
Sheng L; Wu CY; Chen XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
[TBL] [Abstract][Full Text] [Related]
4. Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin.
Uehara H; Takahashi T; Izumi K
Int J Oncol; 2013 Aug; 43(2):365-74. PubMed ID: 23708710
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.
Peng X; Guo W; Ren T; Lou Z; Lu X; Zhang S; Lu Q; Sun Y
PLoS One; 2013; 8(3):e58361. PubMed ID: 23516466
[TBL] [Abstract][Full Text] [Related]
6. Effects of icariin on the regulation of the OPG-RANKL-RANK system are mediated through the MAPK pathways in IL-1β-stimulated human SW1353 chondrosarcoma cells.
Wang Z; Ding L; Zhang S; Jiang T; Yang Y; Li R
Int J Mol Med; 2014 Dec; 34(6):1720-6. PubMed ID: 25270538
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
8. Icariin Stimulates hFOB 1.19 Osteoblast Proliferation and Differentiation via OPG/RANKL Mediated by the Estrogen Receptor.
Sun LJ; Li C; Wen XH; Guo L; Guo ZF; Liao LQ; Guo Y
Curr Pharm Biotechnol; 2021; 22(1):168-175. PubMed ID: 31971108
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.
Deligiorgi MV; Panayiotidis MI; Griniatsos J; Trafalis DT
Clin Exp Metastasis; 2020 Feb; 37(1):13-30. PubMed ID: 31578655
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
11. Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.
Zhao H; Cai W; Li S; Da Z; Sun H; Ma L; Lin Y; Zhi D
Childs Nerv Syst; 2013 Jul; 29(7):1097-105. PubMed ID: 23559392
[TBL] [Abstract][Full Text] [Related]
12. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of icariin in regulating bone formation of osteoblasts and bone resorption of osteoclasts].
Ma XN; Ge BF; Chen KM; Zhou J; Shi WG; Xie YF; Guo XY; Lv X; Cheng K; Gao YH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):432-8. PubMed ID: 23987492
[TBL] [Abstract][Full Text] [Related]
15. [Effect of icariin on bone destruction and serum RANKL/OPG levels in type II collagen-induced arthritis rats].
Liu YJ; Feng W; He DY; Wang QQ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Sep; 33(9):1221-5. PubMed ID: 24273978
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Wang J; Chen TY; Qin S; Duan Y; Wang G
Med Hypotheses; 2013 Nov; 81(5):805-6. PubMed ID: 24074896
[TBL] [Abstract][Full Text] [Related]
19. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
20. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]